<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005602</url>
  </required_header>
  <id_info>
    <org_study_id>ADVL0012</org_study_id>
    <secondary_id>COG-ADVL0012</secondary_id>
    <secondary_id>CCG-ADVL0012</secondary_id>
    <secondary_id>ALK-01-042</secondary_id>
    <secondary_id>CCG-09802</secondary_id>
    <secondary_id>CDR0000067715</secondary_id>
    <nct_id>NCT00005602</nct_id>
  </id_info>
  <brief_title>Radiation Therapy Plus Carboplatin and Lobradimil in Treating Children With Newly Diagnosed Brain Stem Gliomas</brief_title>
  <official_title>Phase I Study of Concurrent Cereport and Carboplatin With Radiation Therapy for Children With Newly-Diagnosed Brain Stem Gliomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs such as
      carboplatin and lobradimil may make the tumor cells more sensitive to radiation therapy.

      PURPOSE: Phase I trial to study the effectiveness of combining radiation therapy with
      carboplatin and lobradimil in treating children who have newly diagnosed brain stem gliomas.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the maximum tolerated duration of lobradimil plus carboplatin with
           radiotherapy in patients with newly diagnosed brain stem gliomas.

        -  Determine the toxic effects of this treatment regimen in these patients.

        -  Assess the response to radiotherapy in patients treated with this regimen.

      OUTLINE: Patients receive radiotherapy for 5 consecutive days a week for 6.5 weeks, for a
      total of 33 doses. Patients receive carboplatin IV over 15 minutes followed by lobradimil IV
      over 10 minutes concurrently with radiotherapy.

      The first cohort of 3-6 patients receives treatment with carboplatin and lobradimil for the
      first three weeks of radiotherapy, with the duration of chemotherapy increasing by one week
      with each subsequent cohort until the maximum duration of 6.5 weeks is reached or until
      unacceptable toxicity occurs in 2 of 6 patients.

      Patients are followed at 6 weeks; every 3 months for 2 years; every 6 months for 3 years; and
      then annually thereafter.

      PROJECTED ACCRUAL: A total of 15-24 patients will be accrued for this study within 36 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2001</start_date>
  <completion_date type="Actual">September 2005</completion_date>
  <primary_completion_date type="Actual">January 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <description>A MRI scan will be performed six (6) weeks after completion of radiation, plus at three-month intervals thereafter for two years, as long as there is no evidence of progressive disease. Children who are progression-free two years after treatment will have MRI scanning at six-month intervals, thereafter, for three more years</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <arm_group>
    <arm_group_label>Radiation Therapy, 33 Doses; Carboplatin 35mg^m2 for 20 Days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Radiation Therapy, 33 Doses; Carboplatin 35mg^m2 for 25 Days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Radiation Therapy, 33 Doses; Carboplatin 35mg^m2 for 30 Days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Radiation Therapy, 33 Doses; Carboplatin 35mg^m2 for 33 Days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <arm_group_label>Radiation Therapy, 33 Doses; Carboplatin 35mg^m2 for 20 Days</arm_group_label>
    <arm_group_label>Radiation Therapy, 33 Doses; Carboplatin 35mg^m2 for 25 Days</arm_group_label>
    <arm_group_label>Radiation Therapy, 33 Doses; Carboplatin 35mg^m2 for 30 Days</arm_group_label>
    <arm_group_label>Radiation Therapy, 33 Doses; Carboplatin 35mg^m2 for 33 Days</arm_group_label>
    <other_name>Paraplatin</other_name>
    <other_name>CBDCA</other_name>
    <other_name>NSC #241240</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cereport</intervention_name>
    <arm_group_label>Radiation Therapy, 33 Doses; Carboplatin 35mg^m2 for 20 Days</arm_group_label>
    <arm_group_label>Radiation Therapy, 33 Doses; Carboplatin 35mg^m2 for 25 Days</arm_group_label>
    <arm_group_label>Radiation Therapy, 33 Doses; Carboplatin 35mg^m2 for 30 Days</arm_group_label>
    <arm_group_label>Radiation Therapy, 33 Doses; Carboplatin 35mg^m2 for 33 Days</arm_group_label>
    <other_name>labradimil</other_name>
    <other_name>IND #60315</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <arm_group_label>Radiation Therapy, 33 Doses; Carboplatin 35mg^m2 for 20 Days</arm_group_label>
    <arm_group_label>Radiation Therapy, 33 Doses; Carboplatin 35mg^m2 for 25 Days</arm_group_label>
    <arm_group_label>Radiation Therapy, 33 Doses; Carboplatin 35mg^m2 for 30 Days</arm_group_label>
    <arm_group_label>Radiation Therapy, 33 Doses; Carboplatin 35mg^m2 for 33 Days</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Newly diagnosed diffuse, intrinsic brain stem gliomas

          -  Measurable disease

          -  No disseminated disease at sites other than brain stem

          -  No neurofibromatosis

          -  Treatment must begin within 31 days of diagnosis

               -  Date of diagnosis will be considered date of surgery in patients undergoing
                  surgical biopsy

        PATIENT CHARACTERISTICS:

        Age:

          -  3 to 21

        Performance status:

          -  Karnofsky 50-100% (over 10 years of age)

          -  Lansky 50-100% (10 years of age and under)

        Life expectancy:

          -  At least 2 months

        Hematopoietic:

          -  Absolute neutrophil count at least 1,500/mm^3

          -  Platelet count at least 100,000/mm^3

          -  Hemoglobin at least 10 g/dL

        Hepatic:

          -  Bilirubin less than 1.5 times upper limit of normal (ULN)

          -  SGPT no greater than 2.5 times ULN (4.0 times ULN with antiepileptic or steroid
             medications)

        Renal:

          -  Creatinine less than ULN for age OR

          -  Creatinine clearance or glomerular filtration rate greater than 80 mL/min

        Other:

          -  No history of severe allergic reaction to any platinum-containing compound

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  No concurrent growth factors during therapy with carboplatin

        Chemotherapy

          -  Not specified

        Endocrine therapy

          -  Prior corticosteroids for brain stem glioma are allowed

        Radiotherapy

          -  Not specified

        Surgery

          -  Prior surgery for brain stem glioma is allowed

        Other

          -  At least 24 hours since any of the following medications:

               -  Vasodilating compounds

               -  Angiotensin-converting enzyme inhibitors

               -  Calcium channel blockers

               -  Beta blockers

          -  No other prior therapy for brain stem glioma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roger J. Packer, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Children's Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027-0700</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lucile Packard Children's Hospital at Stanford</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143-0128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010-2970</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202-5289</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MBCCOP - LSU Health Sciences Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216-4505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Einstein Clinical Cancer Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herbert Irving Comprehensive Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State University of New York - Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Medical Center - Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Doernbecher Children's Hospital</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97201-3098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas - MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital and Regional Medical Center - Seattle</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 2, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>February 19, 2014</last_update_submitted>
  <last_update_submitted_qc>February 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>untreated childhood brain stem glioma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

